XTL Biopharmaceuticals Ltd. (TLV:XTLB)
Israel
· Delayed Price · Currency is ILS · Price in ILA 4.600
+0.100 (2.22%)
May 13, 2025, 5:24 PM IDT
XTL Biopharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 0.37 | 1.4 | 2.09 | 2.97 | 3.63 | Upgrade
|
| Trading Asset Securities | 0.77 | 0.61 | 1.63 | 3.16 | 2.41 | Upgrade
|
| Cash & Short-Term Investments | 1.14 | 2.01 | 3.72 | 6.13 | 6.04 | Upgrade
|
| Cash Growth | -43.02% | -46.09% | -39.27% | 1.41% | -10.20% | Upgrade
|
| Accounts Receivable | 0.1 | - | - | - | - | Upgrade
|
| Receivables | 0.1 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 0.05 | 0.03 | 0.07 | 0.09 | 0.07 | Upgrade
|
| Other Current Assets | 0.05 | 0.01 | 0.01 | 0.02 | 0.01 | Upgrade
|
| Total Current Assets | 1.34 | 2.05 | 3.81 | 6.24 | 6.12 | Upgrade
|
| Property, Plant & Equipment | 0.19 | - | - | 0 | 0 | Upgrade
|
| Goodwill | 3.19 | - | - | - | - | Upgrade
|
| Other Intangible Assets | 3.82 | 0.38 | 0.38 | 0.38 | 0.38 | Upgrade
|
| Other Long-Term Assets | 0.01 | - | - | - | - | Upgrade
|
| Total Assets | 8.55 | 2.43 | 4.19 | 6.62 | 6.5 | Upgrade
|
| Accounts Payable | 0.23 | 0 | 0 | 0 | 0 | Upgrade
|
| Accrued Expenses | 0.55 | 0.21 | 0.19 | 0.23 | 0.25 | Upgrade
|
| Short-Term Debt | 0.14 | - | - | - | - | Upgrade
|
| Current Unearned Revenue | 0.02 | - | - | - | - | Upgrade
|
| Other Current Liabilities | 1.28 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 2.21 | 0.21 | 0.19 | 0.23 | 0.25 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 0.22 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 0.69 | - | - | 1.05 | 2.64 | Upgrade
|
| Total Liabilities | 3.12 | 0.21 | 0.19 | 1.29 | 2.89 | Upgrade
|
| Common Stock | 23.14 | 14.12 | 14.12 | 14.12 | 13.18 | Upgrade
|
| Additional Paid-In Capital | 141.29 | 146.33 | 146.33 | 146.33 | 146.02 | Upgrade
|
| Retained Earnings | -159.01 | -158.25 | -156.47 | -155.13 | -155.61 | Upgrade
|
| Comprehensive Income & Other | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | Upgrade
|
| Total Common Equity | 5.44 | 2.22 | 4 | 5.33 | 3.61 | Upgrade
|
| Shareholders' Equity | 5.44 | 2.22 | 4 | 5.33 | 3.61 | Upgrade
|
| Total Liabilities & Equity | 8.55 | 2.43 | 4.19 | 6.62 | 6.5 | Upgrade
|
| Total Debt | 0.14 | - | - | - | - | Upgrade
|
| Net Cash (Debt) | 1.01 | 2.01 | 3.72 | 6.13 | 6.04 | Upgrade
|
| Net Cash Growth | -49.90% | -46.09% | -39.27% | 1.41% | -10.20% | Upgrade
|
| Net Cash Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Filing Date Shares Outstanding | 881.39 | 544.91 | 544.91 | 544.91 | 514.21 | Upgrade
|
| Total Common Shares Outstanding | 881.39 | 544.91 | 544.91 | 544.91 | 514.21 | Upgrade
|
| Working Capital | -0.87 | 1.84 | 3.62 | 6.01 | 5.87 | Upgrade
|
| Book Value Per Share | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Tangible Book Value | -1.57 | 1.84 | 3.62 | 4.95 | 3.23 | Upgrade
|
| Tangible Book Value Per Share | -0.00 | 0.00 | 0.01 | 0.01 | 0.01 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.